Bryan Selby

5.1k total citations · 2 hit papers
11 papers, 3.7k citations indexed

About

Bryan Selby is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Genetics. According to data from OpenAlex, Bryan Selby has authored 11 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Genetics. Recurrent topics in Bryan Selby's work include Prostate Cancer Treatment and Research (8 papers), Hormonal and reproductive studies (6 papers) and Estrogen and related hormone effects (4 papers). Bryan Selby is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Hormonal and reproductive studies (6 papers) and Estrogen and related hormone effects (4 papers). Bryan Selby collaborates with scholars based in United States, France and Canada. Bryan Selby's co-authors include Fred Saad, Neal D. Shore, Howard I. Scher, Mary‐Ellen Taplin, Johann S. de Bono, Karim Fizazi, Ronald de Wit, Mohammad Hirmand, Kurt Miller and Cora N. Sternberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancers.

In The Last Decade

Bryan Selby

9 papers receiving 3.6k citations

Hit Papers

Increased Survival with Enzalutamide in Prostate Cancer a... 2012 2026 2016 2021 2012 2020 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Howard I. Scher, Karim Fizazi et al. New England Journal of Medicine profile →
  2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    2020 259 citations Neal D. Shore, Fred Saad et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bryan Selby United States 5 3.3k 1.1k 1.0k 917 848 11 3.7k
Susan Feyerabend United Kingdom 21 3.2k 1.0× 1.0k 0.9× 1.1k 1.1× 1.0k 1.1× 726 0.9× 71 3.9k
Peter De Porre United States 26 2.5k 0.8× 893 0.8× 854 0.8× 761 0.8× 730 0.9× 91 3.4k
Mohammad Hirmand United States 18 4.6k 1.4× 1.6k 1.5× 1.6k 1.6× 1.3k 1.4× 1.2k 1.4× 38 5.2k
Dana E. Rathkopf United States 35 3.8k 1.2× 1.3k 1.1× 1.4k 1.4× 1.7k 1.9× 1.6k 1.9× 203 5.3k
Russell Z. Szmulewitz United States 25 2.0k 0.6× 554 0.5× 756 0.7× 888 1.0× 829 1.0× 121 2.9k
Simon Chowdhury United Kingdom 29 4.0k 1.2× 1.3k 1.2× 1.4k 1.4× 1.4k 1.5× 1.0k 1.2× 199 5.1k
Mary Ellen Taplin United States 16 4.2k 1.3× 962 0.9× 1.0k 1.0× 1.6k 1.7× 924 1.1× 27 5.1k
Luis Fein Argentina 18 2.6k 0.8× 727 0.6× 1.3k 1.3× 1.7k 1.8× 530 0.6× 52 3.8k
J Horti Hungary 9 3.6k 1.1× 1.2k 1.0× 1.1k 1.1× 1.6k 1.8× 1.0k 1.2× 17 4.6k
David Lorente Spain 28 1.8k 0.6× 653 0.6× 1.1k 1.0× 1.2k 1.3× 594 0.7× 100 2.9k

Countries citing papers authored by Bryan Selby

Since Specialization
Citations

This map shows the geographic impact of Bryan Selby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Selby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Selby more than expected).

Fields of papers citing papers by Bryan Selby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Selby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Selby. The network helps show where Bryan Selby may publish in the future.

Co-authorship network of co-authors of Bryan Selby

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Selby. A scholar is included among the top collaborators of Bryan Selby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Selby. Bryan Selby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
George, Daniel J., Fred Saad, Michael S. Cookson, et al.. (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical Genitourinary Cancer. 21(3). 383–392.e2. 6 indexed citations
2.
Saad, Fred, Daniel J. George, Michael S. Cookson, et al.. (2023). Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. Cancers. 15(19). 4854–4854. 3 indexed citations
3.
Cookson, Michael S., Neal D. Shore, Daniel J. George, et al.. (2021). Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.. Journal of Clinical Oncology. 39(15_suppl). 5075–5075. 1 indexed citations
4.
George, Daniel J., Neal D. Shore, Fred Saad, et al.. (2021). Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.. Journal of Clinical Oncology. 39(6_suppl). 106–106. 5 indexed citations
5.
Shore, Neal D., Daniel J. George, Fred Saad, et al.. (2020). HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.. Journal of Clinical Oncology. 38(15_suppl). 5602–5602. 4 indexed citations
6.
Shore, Neal D., Fred Saad, Michael S. Cookson, et al.. (2020). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. New England Journal of Medicine. 382(23). 2187–2196. 259 indexed citations breakdown →
7.
8.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 367(13). 1187–1197. 3326 indexed citations breakdown →
9.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology. 30(5_suppl). LBA1–LBA1. 96 indexed citations
10.
Doody, Rachelle S., Bengt Winblad, Jeffrey L. Cummings, et al.. (2012). O3‐13‐06: Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials. Alzheimer s & Dementia. 8(4S_Part_12). 1 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by Peter De Porre Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by Dana E. Rathkopf Breakdown of academic impact, for papers by Russell Z. Szmulewitz Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by Mary Ellen Taplin Breakdown of academic impact, for papers by Luis Fein Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by David Lorente
Rankless by CCL
2026